Different effects of beta-1-adrenergic blocking agents with ISA or without ISA on peripheral blood flow

Angiology
|April 1, 1987
PubMed

Insights

Celiprolol, a beta-blocker with ISA, did not affect peripheral blood flow in patients with or without peripheral arterial occlusive disease (PAOD). Metoprolol, without ISA, reduced blood flow and increased vascular resistance in these patients.

Area of Science:

  • Cardiology
  • Pharmacology
  • Vascular Medicine

Background:

  • Beta-adrenergic blocking agents were historically contraindicated for peripheral arterial occlusive disease (PAOD).
  • Recent studies suggest some beta-blockers may not negatively impact peripheral blood flow.

Purpose of the Study:

  • To compare the effects of celiprolol (beta-1 blocker with ISA) and metoprolol (beta-1 blocker without ISA) on peripheral blood flow in patients with and without PAOD.

Main Methods:

  • Acute trial: 24 patients (12 with PAOD, 12 without) received single doses of celiprolol or metoprolol in a double-blind crossover design.
  • Long-term trial: Patients received daily doses of celiprolol or metoprolol for three weeks in a randomized double-blind design.
  • Measurements included calf and skin blood flow at rest and during reactive hyperemia, basal vascular resistance (BVR), and minimal vascular resistance (MVR).

Main Results:

  • Celiprolol did not significantly alter blood flow or vascular resistance in either group during acute or long-term treatment.
  • Metoprolol significantly reduced muscle blood flow and increased BVR acutely in both groups.
  • Long-term metoprolol treatment lowered calf blood flow at rest in PAOD patients and in non-PAOD patients, also increasing BVR in the latter.

Conclusions:

  • Celiprolol appears safe for peripheral circulation in patients with and without PAOD.
  • Metoprolol may negatively impact peripheral blood flow, particularly in patients with PAOD, warranting caution.

Related Concept Videos

Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...